Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Total Liabilities (2019 - 2025)

IDEAYA Biosciences' Total Liabilities history spans 7 years, with the latest figure at $86.4 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 33.02% year-over-year to $86.4 million; the TTM value through Dec 2025 reached $86.4 million, up 33.02%, while the annual FY2025 figure was $86.4 million, 33.02% up from the prior year.
  • Total Liabilities for Q4 2025 was $86.4 million at IDEAYA Biosciences, down from $93.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $93.1 million in Q3 2025 and bottomed at $24.9 million in Q3 2023.
  • The 5-year median for Total Liabilities is $66.8 million (2022), against an average of $60.1 million.
  • The largest annual shift saw Total Liabilities soared 632.75% in 2021 before it tumbled 62.22% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $79.8 million in 2021, then tumbled by 51.76% to $38.5 million in 2022, then fell by 26.71% to $28.2 million in 2023, then soared by 130.09% to $64.9 million in 2024, then surged by 33.02% to $86.4 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Total Liabilities are $86.4 million (Q4 2025), $93.1 million (Q3 2025), and $81.6 million (Q2 2025).